- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Ferric derisomaltose plus tranexamic acid may reduce blood transfusion risk by 50% in hip surgery
Hip fractures are a common and serious injury, particularly among the elderly, often requiring surgery. Anaemia and the subsequent need for blood transfusion can complicate recovery and increase the risk of poor outcomes. A recent double-blind, randomized trial published in The Lancet Haematology conducted in France by Prof. Sigismond Lasocki and colleagues have shed light on a promising approach to reducing blood transfusion rates in patients undergoing hip fracture surgery.
A randomized double-blind factorial trial involving 413 patients aged 51 to 104 years, with a median age of 86 (IQR 78-91) and 76% women, assessed the impact of intravenous iron and tranexamic acid on blood transfusion rates following hip fracture surgery. Conducted from March 31, 2017, to June 18, 2021, the study allocated participants to four groups: iron + tranexamic acid (n=104), iron + placebo (n=103), tranexamic acid + placebo (n=103), and double placebo (n=103), with an interim analysis conducted on the first 390 participants. The primary outcome was the percentage of patients requiring blood transfusion during hospitalization or by day 30.
● The primary outcome, transfusion percentage, showed a decrease in the iron + tranexamic acid group (15%) compared to the double placebo group (30%), yielding a relative risk of 0.51 (98.3% CI 0.27−0.97; p=0.012).
● Similar transfusion rates were observed in the iron-only (26%) and tranexamic acid-only (27%) groups.
● Adverse event rates were comparable across groups, with common events such as sepsis, pneumonia, and urinary infections.
This study suggests that combining ferric derisomaltose (intravenous iron) and tranexamic acid can significantly reduce the risk of blood transfusion by 50% in patients undergoing hip fracture surgery.
The combination approach highlights the potential benefits of integrating treatments from different therapeutic approaches to improve patient outcomes.
While neither treatment alone showed a significant reduction in transfusion rates in this study, the combined effect proved promising.
These findings contribute to the understanding of blood-management strategies for patients undergoing hip fracture surgery. Further research and larger trials are needed to confirm these results and explore the broader applicability of this combination treatment approach. The study underscores the importance of innovative strategies to enhance patient care and recovery in orthopedic surgery.
Reference:
Lasocki, S., Capdevila, X., Vielle, B., Bijok, B., Lahlou-Casulli, M., Collange, V., Grillot, N., Danguy des Deserts, M., Duchalais, A., Delannoy, B., Drugeon, B., Bouzat, P., David, J.-S., Rony, L., Loupec, T., Léger, M., Rineau, E., Bouhours, G., Lasocki, S., … David, J.-S. (2023). Ferric derisomaltose and tranexamic acid, combined or alone, for reducing blood transfusion in patients with hip fracture (the HiFIT trial): a multicentre, 2 × 2 factorial, randomised, double-blind, controlled trial. The Lancet. Haematology. https://doi.org/10.1016/s2352-3026(23)00163-1
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751